References
- Smuts J. A., de Boulle K., van Coller R., Barnard P. W. A. An electrophysiological study to demonstrate in vivo differences between two types of botulinum toxin type A (BOTOX® and DYSPORT®). Poster presented at the 8th International Congress of Parkinson's Disease and Movement Disorder, RomeItaly, June 13–17, 2004
- Lowe P., Patnaik R., Lowe N. Comparison of two formulations of botulinum toxin type A for the treatment of glabellar lines: A double‐blind, randomized study. J Am Acad Dermatol 2006; 55: 975–80, Epub 2006 Oct 6
- Trindade de Almeida A. R., Marques E., de Almeida J., Cunha T., Boraso R. Pilot study comparing the diffusion of two formulations of botulinum toxin type A in patients with forehead hyperhidrosis. Dermatol Surg 2007; 33((suppl 1))S37–43
- Cliff S. H., Judodihardjo H., Eltringham E. Different formulations of botulinum toxin type A have different migration characteristics: a double‐blind, randomized study. J Cosmet Dermatol 2008; 7: 50–54
- Lew H., Yun Y. S., Lee S. Y., Kim S. J. Effect of botulinum toxin A on facial wrinkle lines in Koreans. Ophthalmologica 2002; 216: 50–4
- Nüβgens Z., Roggenkamper P. Comparison of two botulinum‐toxin preparations in the treatment of essential blepharospasm. Graefes Arch Clin Exp Ophthalmol 1997; 235: 197–9
- Ranoux D., Gury C., Fondarai J., Mas J. L., Zuber M. Respective potencies of Botox and Dysport: A double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry 2002; 72: 459–62
- Dodel R. C., Kirchner A., Koehne‐Volland R., Künig G., Ceballos‐Baumann A., Naumann M., et al. Costs of treating dystonias and hemifacial spasm with botulinum toxin A. Pharmacoeconomics 1997; 12: 695–706
- Simonetta Moreau M., Cauhepe C., Magues J. P., Senard J. M. A double‐blind, randomized, comparative study of Dysport® vs. Botox® in primary palmar hyperhidrosis. Br J Dermatol 2003; 149: 1041–5
- Roche N., Schnitzler A., Genêt F., Durand M. C., Bensmail D. Uncontrolled migration outside the targeted muscle associated with adverse effect of botulinum toxin type A distant from the injection site: A preliminary analysis. Undesirable distant effects following botulinum toxin type‐A injection. Clinical Neuropharmacology 2008, (in press)
- BOTOX® COSMETIC prescribing information. Accessed 13 February 2007. URL: http://www.botoxcosmetic.com/pi/pi.pdf.
- Ascher B., Zakine B., Kestemont P., Baspeyras M., Bougara A., Santini J. A multicenter, randomized, double‐blind, placebo‐controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. J Am Acad Dermatol 2004; 51: 223–33
- Monheit G., Carruthers A., Brandt F., Rand R. A randomized, double‐blind, placebo‐controlled study of botulinum toxin type A for the treatment of glabellar lines: Determination of optimal dose. Dermatol Surg 2007; 33((1 Spec No.))S51–9
- Carruthers A., Carruthers J., Said S. Dose‐ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females. Dermatol Surg 2005; 31: 414–22
- Cox S. E., Finn J. C., Stetler L., Mackowiak J., Kowalski J. W. Development of the Facial Lines Treatment Satisfaction Questionnaire and initial results for botulinum toxin type A‐treated patients. Dermatol Surg 2003; 29: 444–9
- Stotland M. A., Kowalski J. W., Ray B. B. Patient‐reported benefit and satisfaction with botulinum toxin type A treatment of moderate to severe glabellar rhytides: results from a prospective open‐label study. Plast Reconstr Surg 2007; 120: 1386–93, discussion 1394